Drugs, Bugs or Cancer? A Case of Cholestatic Hepatitis

S Jalil,SY Xiao,SA Weinman

DOI: https://doi.org/10.14309/00000434-200509001-00507

2005-01-01

Abstract:Clarithromycin is a macrolide antibiotic commonly indicated for use in upper and lower respiratory infections and has a well established safety and efficacy profile. Rare case reports of fatal progressive cholestatic and fulminant hepatitis from clarithromycin have been described. We describe a case of acute cholestatic hepatitis from clarithromycin with complete resolution of symptoms on withdrawal. A 48-year-old female with a history of recurrent breast cancer developed Mycobacterium Abscessus pneumonia which was treated with combination of antibiotics including clarithromycin. At the time antibiotics were begun all liver enzymes were normal. Few days after starting treatment she had an isolated increase in alkaline phosphatase to 200 U/dl. Nonetheless, she continued on these drugs for 21 days until it was noted that she had developed jaundice. Liver enzymes revealed a syndrome of cholestatic hepatitis with total bilirubin of 6.9 mg/dl, alkaline phosphatase of 502 U/L, ALT 128 U/L, AST 147 U/L and GGT of 208 U/L. Hepatitic C virus antibody was positive but HCV RNA was undetectable. There was no evidence of extra-hepatic cholestasis on CT of the abdomen. A percutaneous liver biopsy showed acute lobular hepatitis with eosinophilia and cholestasis. A presumptive diagnosis of clarithromycin induced cholestasis was made. Withdrawal of the inciting drug led to a reduction in alkaline phosphatase and bilirubin within 5 days and complete resolution clinically and biochemically in 12 weeks. Clarithromycin is a safe and efficacious macrolide antibiotic. This report emphasizes the possibility of severe idiopathic cholestatic reactions to clarithromycin that are potentially reversible. Therefore awareness and prompt drug discontinuation is critical. [figure 1][figure 2]FigureFigure